We recently showed that FoxM1 is overexpressed in human glioblastomas and that forced FoxM1B expression in anaplastic astrocytoma cells leads to the formation of highly invasive glioblastoma multiforme (GBM) in nude mice. However, the molecular mechanisms by which FoxM1 enhances glioma invasion are unknown. In this study, we found that FoxM1 overexpression increased matrix metalloproteinase (MMP)-2 expression in glioma cells, whereas blockade of FoxM1 expression suppressed MMP-2 expression. Transfection of FoxM1 into glioma cells directly activated the MMP-2 promoter, whereas inhibition of FoxM1 expression by FoxM1-siRNA suppressed its activation. We identified a FoxM1-binding site in the MMP-2 promoter and demonstrated that FoxM1 protein bound directly to it. Mutation of this FoxM1-binding site significantly attenuated MMP-2 promoter activity. Furthermore, FoxM1 overexpression increased the invasiveness of glioma cells, whereas inhibition of FoxM1 expression suppressed the invasiveness of GBM cells. Inhibition of MMP-2 by a specific MMP-2 inhibitor reversed the invasive phenotype of glioma cells overexpressing FoxM1. Finally, immunohistochemical analysis of 45 human GBM specimens showed a significant correlation between FoxM1 overexpression and elevated MMP-2 expression. Collectively, these findings provide evidence that FoxM1 contributes to glioma progression by enhancing MMP-2 gene transcription and thus tumor-cell invasion.
Introduction
FoxM1 is a member of the Forkhead box (Fox) family of transcription factors (Korver et al., 1997; Yao et al., 1997; Ye et al., 1997) known for its function as a transcriptional regulator of the cell cycle. Increasing evidence indicates that FoxM1 may contribute to oncogenesis in some tissues. For example, three groups found FoxM1 expression to be upregulated in cases of basal cell carcinoma, hepatocellular carcinoma and primary breast cancer (Teh et al., 2002; Wonsey and Follettie, 2005) . Other studies showed that aberrant expression of FoxM1 was a common molecular alteration in malignant glioma (Rickman et al., 2001; van den Boom et al., 2003) . In our own studies of the functional significance of this factor, we found that FoxM1B was the predominant FoxM1 isoform in human gliomas but not in normal brain tissue (Liu et al., 2006) . We further found that FoxM1 protein expression level in human glioma tissue correlated directly with the glioma grade and that FoxM1 protein expression level in human glioblastoma tissue correlated inversely with patient survival. FoxM1 also seems to be essential for glioma growth, because glioblastoma multiforme (GBM) cells transfected with FoxM1-small interfering RNA (siRNA) failed to produce brain tumors in most mice after orthotopic implantation. Increased FoxM1B expression in glioma cells enhanced their tumorigenicity, and forced FoxM1B expression in anaplastic astrocytoma cells led to the formation of GBMs, which are highly invasive, in the brains of nude mice (Liu et al., 2006) . These findings underscore the importance of elucidating the molecular mechanisms by which FoxM1 regulates tumor invasion, a crucial aspect of tumor biology.
Gliomas are the most common primary brain tumors in humans and are among the deadliest of all cancers. The poor prognosis and survival rates associated with malignant gliomas reflect their highly invasive nature, which prevents complete tumor resection and remains a major obstacle for any effective therapeutic remedies (Giese et al., 2003) . Acquisition of the invasive phenotype by low-grade glioma is a turning point during glioma progression. Invasion of glioma cells involves the attachment of invading tumor cells to the extracellular matrix (ECM), disruption of the ECM components and subsequent penetration into adjacent brain structures. This process is accomplished in part by tumor-secreted matrix metalloproteinases (MMPs) that degrade the ECM at tumor-invasive fronts to overcome the ECM barrier. The role of MMPs in the process of invasion is well established. In particular, MMP-2, a 72 kDa type IV collagenase, also referred to as gelatinase A, is a key enzyme in the invasion cascade of malignant glioma. Numerous studies have demonstrated that elevated MMP-2 levels correlate with increased invasiveness in a large number of glioma cell lines (Sawaya et al., 1996; Lampert et al., 1998) . Also, MMP-2 expression is significantly higher in glioblastomas than in low-grade astrocytomas, anaplastic astrocytomas and normal brain tissue (Abe et al., 1994; Wild-Bode et al., 2001b) . Along with MMP-9 activity, MMP-2 activity has been reported to be the best predictor of glioma invasion (Wild-Bode et al., 2001b) . Moreover, upregulation of MMP-2 expression by other molecules enhanced glioma invasion in several in vitro and in vivo model systems (Hu et al., , 2006 Wang et al., 2003) . These findings indicate that MMP-2 expression in glioma cells has an important role in glioma invasion.
We show here that the molecular mechanism by which FoxM1 enhances glioma invasion involves the upregulation of MMP-2. We found that FoxM1 binds to and activates the promoter of the MMP-2 gene. Overexpression of FoxM1 in glioma cells by transfection of a FoxM1B expression vector significantly upregulated the expression of MMP-2 and the invasiveness of the glioma cells, whereas inhibition of FoxM1 by transfection of FoxM1-siRNA did the opposite. Our results demonstrate that FoxM1B overexpression contributes directly to MMP-2 overexpression in malignant gliomas and is critical for glioma invasion.
Results

Altered FoxM1 expression affects MMP-2 expression in glioma cells
To determine the effect of increased FoxM1 expression on MMP-2 expression, we studied two human glioma cell lines that have low levels of FoxM1 protein: SW1783 and Hs683 (Liu et al., 2006) . We transfected these cells with the FoxM1B expression vector pcDNA3.1-FoxM1B or the control vector pcDNA3.1. To avoid clonal selection and variation, we pooled neomycin (G418)-resistant colonies to establish stable transfectants and designated them the FoxM1B-transfected cell lines (SW1783-FoxM1 and Hs683-FoxM1). We found that forced expression of FoxM1B in SW1783 and Hs683 cells significantly increased the expression of FoxM1 mRNA and protein (Figure 1a1 and a2 ). These cells also exhibited significantly increased MMP-2 mRNA and enzyme activity (Figure 1a1 and a3) . These results indicate that FoxM1 overexpression in glioma cells increased the expression of MMP-2.
Conversely, to determine the effect of decreased FoxM1 expression on MMP-2 expression, we transfected FoxM1-siRNA (50 nM) into HF-U251MG and U87MG cells, which typically express higher levels of FoxM1 (Liu et al., 2006) . This transfection significantly inhibited FoxM1 mRNA and protein expression in both types of cells ( Figure 1b1 and b2) ; it also resulted in significantly decreased MMP-2 mRNA and enzyme activity in the cells (Figure 1b1 and b3) . These results indicate that blockade of FoxM1 expression suppressed MMP-2 expression. Because MMP-9 collagenase activity levels were quite low, we were unable to determine whether FoxM1 affects MMP-9 expression in these four glioma cell lines.
FoxM1 regulates MMP-2 promoter activity in glioma cells Next, to investigate the role of FoxM1 in regulating MMP-2 transcription, we sought to determine whether FoxM1 regulates MMP-2 promoter activity. Figure 1 Effects of altered FoxM1 expression on MMP-2 expression in human glioma cell lines. (a) Upregulation of MMP-2 mRNA expression and enzymatic activity by FoxM1 overexpression. Cellular mRNA was prepared from parental, control-vector-transfected, and FoxM1 expression-vector-transfected SW1783 and Hs683 cells. FoxM1 and MMP-2 mRNA expression levels were determined from northern blot analysis (a1). FoxM1 protein expression levels were determined by western blot analysis, and MMP-2 enzymatic activity determined by zymography (a2). (b) Downregulation of MMP-2 mRNA expression and enzymatic activity by knockdown of FoxM1 expression. FoxM1 and MMP-2 expression and MMP-2 enzymatic activity in HF-U251MG and U87MG cells transfected with FoxM1-siRNA or control siRNA were determined as described for (a).
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We cotransfected the MMP-2 promoter-luciferase construct pMLuc into SW1783 or Hs683 cells with pcDNA3.1-FoxM1 or the control vector pcDNA 3.1. Co-transfection with pcDNA3.1-FoxM1 activated the luciferase activity driven by the MMP-2 promoter in both cell lines (Figure 2a) . Conversely, to assess the effect of decreased FoxM1 expression on MMP-2 transcription, we knocked down FoxM1 expression by co-transfecting FoxM1-siRNA (50 nM) and the MMP-2 promoter into HF-U251MG and U87MG cells. FoxM1-siRNA inhibited the luciferase activity driven by the MMP-2 promoter in both types of cells (Figure 2b ). These results indicate that FoxM1 expression was involved in MMP-2 promoter activity in glioma cells.
Direct interaction of FoxM1 with the MMP-2 promoter Next, we analysed the sequence of the MMP-2 promoter for the presence of potential FoxM1-binding elements by using the FoxM1 consensus sequence 5 0 -AGAT TGAGTA-3 0 (Yao et al., 1997) . We identified two putative FoxM1-binding elements (referred to as DNA sequences #1 and #2) in the MMP-2 promoter region ( Figure 3a ). To determine whether FoxM1 binds to the MMP-2 promoter, we radiolabeled the double-stranded oligonucleotides of putative FoxM1-binding sites #1 and #2 and used them as probes in an electrophoretic mobility shift assay (EMSA) with nuclear protein prepared from SW1783-FoxM1 cells (Figure 3b ).
Incubating protein extracts with both probes resulted in the formation of one major shifted band ( Figure 3b , lanes 1 and 2), and the band of the #1 probe was much stronger than that of the #2. Moreover, that shifted band could be supershifted by the FoxM1 antibody (lane 3) and competed out by an unlabeled probe (lane 4), indicating that the shifted band represented a FoxM1 DNA-protein complex.
Next, to provide direct proof that FoxM1 is recruited to the endogenous MMP-2 promoter during transcription in vivo, we performed standard chromatin immunoprecipitation (ChIP) assays with SW1783, SW1783-FoxM1, Hs683 and Hs683-FoxM1 cells. After immunoprecipitating the chromatins in all cells, with or without specific antibodies against FoxM1, we tested the precipitated chromatins for the presence of MMP-2 promoter sequences in a 218 bp region (À772 to À554) or a 299 bp region (À1186 to À887) of the MMP-2 promoter that contains the putative FoxM1-binding sites ( Figure 3a ). The 218 bp DNA fragment was amplified from the precipitates by anti-FoxM1 antibodies, but not by control IgG in both SW1783 and Hs683 glioma cell lines (Figure 3c ). These results suggest that endogenous FoxM1 bound the region between À772 and À554 bp of the MMP-2 promoter in both SW1783 and Hs683 cell lines. Moreover, in cells that express high FoxM1 levels (the transfected SW1783-FoxM1 and Hs683-FoxM1 cells), 4-5 times more promoter DNA bound to FoxM1 compared with the same region in cells expressing low FoxM1 levels (SW1783 and Hs683 cells) (Figure 3c ). However, we did not detect binding of FoxM1 to the region between À1186 and À887 bp of the MMP-2 promoter in any of the cell lines tested (data not shown). Collectively, these findings demonstrate that FoxM1 bound directly to the MMP-2 promoter in vitro and in vivo primarily at position À671 to À662 bp.
The FoxM1-binding site is critical for activation of the MMP-2 promoter in glioma cells To assess the functional role of the FoxM1-binding site in MMP-2 gene regulation, we performed site-directed mutagenesis within the FoxM1-binding site of the MMP-2 promoter (Figure 4a ). We transfected the mutant luciferase reporter construct (Mut) into the HF-U251MG and SW1783-FoxM1 cell lines and compared their activity with that of native MMP-2 promoter pMLuc (WT) (Figure 4b) . A base-pair change from GA to CC in this FoxM1-binding site significantly attenuated MMP-2 promoter activity in both cell lines. These results suggest that the FoxM1-binding site was critical for MMP-2 promoter activation in glioma cells.
Altered FoxM1 expression affects glioma cell invasion
We previously showed that increased FoxM1 expression in anaplastic astrocytoma cells leads to the formation of invasive glioblastomas (Liu et al., 2006) . Because MMP-2 is known to promote tumor invasion, we next analysed whether the expression of MMP-2 by 
FoxM1 overexpression correlates with MMP-2 expression in glioblastoma specimens
To confirm further the clinical relevance of our in vitro observations that FoxM1 regulates MMP-2 gene expression, we analysed FoxM1 and MMP-2 expression in 45 human GBM specimens by immunohistochemical staining. Staining was quantified according to both the percentage of positive cells and staining intensity and assigned a score ranging 0-8. We analysed the scores and found a significant correlation between the FoxM1 and MMP-2 expression levels (r ¼ 0.617; Po0.001) (Figure 6a ). Examples of both positive and negative staining for FoxM1 and MMP-2 are shown in Figure 6b . Furthermore, we performed Western blot analyses using total protein extracts from nine human GBM frozen tissues. As shown in Figure 6c , the expression of MMP-2 correlated with the expression of FoxM1. Therefore, these results suggest that FoxM1 contributed to glioma progression by enhancing MMP-2 gene transcription and glioma cell invasion. 
FoxM1B in glioma invasion B Dai et al
Discussion
Several studies have shown that increased expression of FoxM1 is one of the most common alterations in GBMs (Rickman et al., 2001; van den Boom et al., 2003) . Our recent study further showed that FoxM1 protein expression level in human glioblastoma tissues was inversely correlated with patient survival (Liu et al., 2006) . Elucidating the cellular functions of FoxM1 to determine how it contributes to tumor growth in vivo is important, because clinical and experimental evidence has shown that aberrant FoxM1 expression critically regulates the tumorigenicity of human glioma cells (Liu et al., 2006) . Many studies have indicated the importance of FoxM1 in cell proliferation, as it is a key cell-cycle regulator of both the transition from G 1 to S phase and the progression to mitosis. Presumably, FoxM1 affects the cell cycle through its actions on the expression of genes essential for G 1 /S and G 2 /M progression and for chromosomal stability and segregation, such as Nek2, KIF20A, CENP-A, CENP-F, CDc25A, CDc25B, p27
Kip1 and cyclin D1 (Ye et al., 1999; Laoukili et al., 2005; Wonsey and Follettie, 2005) .
In the present study, we demonstrated that FoxM1 also has an important role in the invasion of GBM cells by regulating the expression of MMP-2, a key proteolytic enzyme in glioma invasion. MMP-2 expression is known to be regulated by several transcription factors, including YB-1, Sp1, Stat3 and p53 (Bian and Sun, 1997; Mertens et al., 1997; Qin et al., 1999; Xie et al., 2004) . Sp1-binding sites are involved in the basal activity of the MMP-2 promoter (Qin et al., 1999) . The role of Stat3 in the expression of MMP-2 in GBM cells is not known; in some studies, Stat3 was often activated in GBM cells, whereas in others Stat3 was not activated in most GBM cells (Konnikova et al., 2003; Wang et al., 2004) . Also, p53 has been shown not to contribute to MMP-2 promoter activity in astroglioma cells (Qin et al., 1999) . 
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In the current study, we identified a FoxM1-binding site mapped between À671 and À662 bp of the proximal MMP-2 promoter, and we found that FoxM1 regulated MMP-2 expression through direct interaction with the MMP-2 promoter. Mutation of the FoxM1-binding site significantly downregulated MMP-2 promoter activity in malignant glioma cells, indicating that this site was crucial for MMP-2 promoter activity in these cells. Moreover, we used the FoxM1 expression and siRNA-knockdown systems and showed that increasing FoxM1 expression upregulated MMP-2 expression, whereas inhibiting FoxM1 expression significantly downregulated MMP-2 expression in glioma cells. Thus, our results demonstrate that increased MMP-2 expression could be attributed to increased expression of the transcription factor FoxM1 in glioma cells. We further found that specifically inhibiting MMP-2 reversed the invasive phenotype of FoxM1-overexpressing glioma cells. Overexpression of FoxM1 increased the invasiveness of glioma cells, whereas inhibition of FoxM1 expression significantly suppressed the invasiveness of GBM cells. Finally, immunohistochemical analysis showed a significant correlation between overexpression of FoxM1 and elevated expression of MMP-2 in 45 GBM specimens. Therefore, our study is the first to describe a molecular mechanism by which FoxM1 promotes tumor-cell invasion.
The mechanisms responsible for the overexpression of FoxM1 in malignant gliomas are not known. FoxM1 expression can be regulated by diverse stimuli, including liver regeneration, keratinocyte growth factor and oxidative stress (Ye et al., 1997) . MMP-2 expression in gliomas may also be regulated by a variety of factors, including angiopoietin-2, insulin-like growth factor binding protein (IGFBP)-2, and phosphatase and tensin homology (PTEN) (Koul et al., 2001; Guo et al., 2003; Hu et al., 2003 Hu et al., , 2006 Wang et al., 2003) . Angiopoietin-2 stimulates MMP-2 expression through the integrin avb1 and focal adhesion kinase signaling pathway (Hu et al., 2006) . IGFBP-2 expression correlates positively with MMP-2 promoter activity in gliomas, although transcriptional regulation of MMP-2 is probably not attributable to the direct action of IGFBP-2 . Whether these abnormal pathways lead to aberrant FoxM1B expression in malignant gliomas is actively being investigated in our laboratory. In addition, a recent publication indicated that ionizing radiation caused an increase in levels of FoxM1 protein in osteosarcoma U2OS cells (Tan et al., 2007) . We have found that ionizing radiation caused an increase in levels of FoxM1 and MMP-2 proteins in glioma cells (Dai B and Huang S, unpublished results) , suggesting the FoxM1-MMP-2 pathway might be activated in response to radiotherapy. Interestingly, previous studies have shown that radiotherapy induced MMP-2 expression in and invasion of glioma cells (Wild-Bode et al., 2001a; Park et al., 2006) . Future studies will be to determine whether FoxM1 induction is a critical event for radiotherapy-enhanced invasion of glioma cells.
In summary, we showed here that overexpression of FoxM1 in malignant glioma cells contributes directly to overexpression of MMP-2 and hence the induction of glioma cell invasion. Conversely, inhibition of FoxM1 expression suppressed MMP-2 expression by GBM and suppressed their invasion. These results suggest that FoxM1 expression is critical for the invasiveness of malignant gliomas. Because FoxM1 has diverse roles in glioma progression, including regulation of tumor-cell proliferation and tumor invasion, a molecular-level understanding of the functions of FoxM1 may provide important information for identifying potential targets for novel therapeutic strategies against malignant glioma. 
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Materials and methods
Cell lines and culture conditions
The resources and culture condition of human glioma cell lines SW1783, Hs683, HF-U251MG and U87MG were described previously (Liu et al., 2006) .
Stable transfection of glioma cells with FoxM1B or a control vector SW1783 and Hs683 cells were transfected with pcDNA3.1-FoxM1B or control vector pcDNA3.1 plasmids. Stably transfected cell lines were isolated by selection with G418. To avoid clonal selection, all of the G418-resistant colonies were pooled to establish stable transfectants.
Northern blot analysis Cellular mRNA was extracted from glioma cells. mRNA was fractionated on a 1% denaturing formaldehyde agarose gel, electrotransferred onto nylon membranes and cross-linked with ultraviolet light. Northern blot hybridization was carried out with [
32 P]dCTP-radiolabeled FoxM1 or MMP-2 cDNA probes (Xie et al., 2004; Liu et al., 2006) .
Western blot analysis
Whole-cell lysates and nuclear proteins were prepared from glioma cells or frozen human glioma tissues (Huang et al., 1998) . Standard Western blotting was performed with a polyclonal rabbit antibody against human FoxM1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), or an anti-MMP-2 antibody (AB 809; Chemicon International, Temecula, CA, USA).
Gelatin zymography
Zymography was carried out according to a previously described procedure (Huang et al., 2002) . Tumor cells (2 Â 10 5 ) were seeded in six-well plates and incubated overnight at 371C. The cells were washed twice with Hanks' balanced salt solution and cultured for an additional 24 h in serum-free medium. Culture supernatants were collected for assays of collagenase activity.
Electrophoretic mobility shift assay EMSA was performed as described previously (Huang et al., 1998) . The double-stranded oligonucleotides of putative FoxM1-binding sites in the MMP-2 promoter were used as probes. For supershift analyses, the cell extracts were preincubated with specific antibodies against FoxM1 (Santa Cruz Biotechnology).
Promoter reporters and dual luciferase assays Glioma cells were transfected with the MMP-2 promoter reporter plasmids. Transfection efficiency was normalized by cotransfection with a pB-actin-RL reporter containing a fulllength Renilla luciferase gene (Huang et al., 1998) . Both firefly luciferase activity and Renilla luciferase activity were quantified by using the dual-luciferase assay system (Promega, Madison, WI, USA). Specific MMP-2 promoter activity was calculated as described previously (Huang et al., 1998) .
Chromatin immunoprecipitation assays Details are described in Supplementary Information.
Site-specific mutagenesis
Site-specific mutagenesis of the MMP-2 promoter was performed with the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions. Mutations were confirmed by DNA sequencing.
Matrigel invasion assay
An in vitro invasion assay was carried out as described previously (Huang et al., 2002) . In some experiments, tumor cells were pretreated with the MMP-2 inhibitor OA-Hy (Calbiochem, San Diego, CA, USA).
Primary human glioma specimens and immunohistochemical analyses Details are described in Supplementary Information.
Statistics
Correlations between positive staining for FoxM1 and positive staining for MMP-2 in the glioma specimens were assessed with Pearson's correlation test. The significance of the in vitro results was determined with Student's t-test (two-tailed), whereas the significance of the in vivo results was determined with the Mann-Whitney U-test.
